Recent:Qiao.
Proxalutamide has been officially adopted
in all or part of 3 countries.
Submit updates/corrections .
Jul 17 |
et al., PNAS, doi:10.1073/pnas.222180912 | Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response |
| In Vitro study showing dose-dependent inhibition of multiple SARS-CoV-2 variants with proxalutamide. Authors find that proxalutamide increased levels of NRF2 and decreased lung inflammation. Authors conclude that there is compelling evide.. | ||
Jun 9 2022 |
, F. | Frontiers Fraudulent Retraction |
| Details on the censorship of [McCoy]. | ||
Apr 8 2022 |
et al., AACR Annual Meeting 2022 | Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients |
| Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC50 of 69, 48 and 39nM. Only the abstract is currently avail.. | ||
Apr 5 2022 |
News Release | Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study |
| 50% lower hospitalization (p=0.38) and 74% improved viral clearance (p=0.0001). RCT 733 outpatients, 99% in the USA, showing lower hospitalization/death, and significantly reduced viral load with proxalutamide treatment. The viral clearance result is from [Ma]. | ||
Dec 27 2021 |
, News Releease | Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19 |
| News release reporting on interim analysis of NCT04870606, showing that statistical criteria were not met, there was a very low event rate, and that Kintor plans to amend the protocol and continue to enroll higher risk patients. | ||
Dec 25 2021 |
et al., Cureus, doi:10.7759/cureus.20691 | Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial |
| 78% lower mortality (p<0.0001), 45% improved recovery (p<0.0001), and 33% shorter hospitalization (p=0.0001). RCT 778 hospitalized patients in Brazil, 423 treated with proxalutamide, showing significantly lower mortality and improved recovery with treatment. NCT04728802 and NCT05126628. Authors note that cases in this trial were predominantly the.. | ||
Dec 17 2021 |
, News Comments | 开拓药业普克鲁胺治疗新冠预计本月发布临床数据 |
| News report noting that real-world results for proxalutamide in Paraguay show significantly lower mortality and are consistent with the results of previous studies in Brazil. | ||
Jul 25 2021 |
et al., medRxiv, doi:10.1101/2021.07.24.21261047 | Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial) |
| Analysis of data from two proxalutamide early treatment RCTs with 445 patients showing substantial improvements in immunologic, inflammatory, thrombotic, and oxygen markers, which may support the observed reduction in hospitalization. | ||
Jul 16 2021 |
Pharmaceutical News Release | Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay |
| News release announcing that proxalutamide has been granted an emergency use authorization for COVID-19 in Paraguay. | ||
Jul 10 2021 |
et al., medRxiv, doi:10.1101/2021.07.06.21260086 | Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial |
| 90% lower ventilation (p=0.07) and 86% lower hospitalization (p=0.0008). RCT 177 women in Brazil, 75 treated with proxalutamide, showing significantly lower hospitalization with treatment. | ||
Jul 2 2021 |
et al., medRxiv, doi:10.1101/2021.06.28.21259661 | Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration - an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial |
| Analysis of treatment duration in the Proxa-Rescue AndroCoV trial showing significantly higher mortality among patients that interrupted treatment with proxalutamide. NCT04728802. | ||
Jul 1 2021 |
et al., ResearchGate | Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial |
| Analysis of radiological findings from the Proxa-Rescue AndroCoV trial showing that proxalutamide significantly improves lung opacities compared to placebo. NCT04728802. | ||
Feb 22 2021 |
et al., Cureus, doi:10.7759/cureus.13492 | Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial |
| 92% improved viral clearance (p<0.0001) and 77% improved recovery (p<0.0001). RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery. Third party analysis suggests potential randomization failure: [steamtraen.blogspot.com]. | ||
Dec 30 2020 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2021.668698 (date from preprint) | Proxalutamide (GT0918) Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial |
| 97% lower ventilation (p<0.0001) and 91% lower hospitalization (p<0.0001). RCT 268 male patients in Brazil, 134 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429. This paper was censored without details or author response, and the editors have ignored.. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.